Kailine Hynes, MA, SLP-CCC in Addison, TX - Speech-Language Pathologist

Kailine Hynes, MA, SLP-CCC is a Speech-language Pathologist based in Addison, Texas. Kailine Hynes is licensed to practice in Texas (license number ) and her current practice location is 15820 Addison Rd, Addison, Texas. She can be reached at her office (for appointments etc.) via phone at (760) 815-4926.

NPI number for Kailine Hynes is 1083127716 and her current mailing address is 9605 Thomas Jefferson Dr, Mckinney, Texas. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1083127716.

Contact Information

	Kailine Hynes, MA, SLP-CCC
	15820 Addison Rd, Addison, TX 75001-3549
	(760) 815-4926
	Not Available

Healthcare Provider's Profile

Full Name	Kailine Hynes
Gender	Female
Speciality	Speech-language Pathologist
Location	15820 Addison Rd, Addison, Texas
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1083127716
Provider Enumeration Date: 11/16/2017
Last Update Date: 11/16/2017

Medical Identifiers

Medical identifiers for Kailine Hynes such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1083127716	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
235Z00000X	Speech-language Pathologist	(Texas)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Kailine Hynes is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Kailine Hynes, MA, SLP-CCC 9605 Thomas Jefferson Dr, Mckinney, TX 75070-8424 Ph: () -	Kailine Hynes, MA, SLP-CCC 15820 Addison Rd, Addison, TX 75001-3549 Ph: (760) 815-4926

News Archive

FDA approves use of Menactra for booster vaccination against meningococcal disease

Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration approved use of Menactra® [Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] for booster vaccination against meningococcal disease in persons 15 years through 55 years of age.

United Therapeutics announces FDA approval of dinutuximab for treatment of high-risk neuroblastoma

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Unituxin (dinutuximab) Injection (formerly called ch14.18), in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Study: Racial disparities found in oral anticoagulant use

Black patients with atrial fibrillation are significantly less likely to receive oral anticoagulants-particularly newer, more effective versions-than white and Hispanic patients, according to a new study published today in JAMA Cardiology.

Financial Times examines global food security issues

This Financial Times analysis examines food security, writing, "Climate change, ill-judged policies, protectionism, urbanization and plain greed have all conspired to reignite Malthusian prophesies of a growing world population unable to feed itself."

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

When the prestigious British medical journal The Lancet Oncology this week published six cancer treatment guideline papers aimed at the resource-diverse nations of Asia, it used as its model the economic template developed by the Breast Health Global Initiative (BHGI) based at Fred Hutchinson Cancer Research Center.

Speech-Language Pathologist in Addison, TX

Shannon Amber Kallsen, M.S. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15820 Addison Rd, Addison, TX 75001 Phone: 866-919-3240
Peyton Martin Howells, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15305 Dallas Pkwy Ste 1200, Addison, TX 75001 Phone: 972-851-1022
Elizabeth Grigerek, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15820 Addison Rd, Addison, TX 75001 Phone: 866-919-3240
Ms. Emily Paige Wilson, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15820 Addison Rd, Addison, TX 75001 Phone: 866-919-3240
Sarah Burgess, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 14673 Midway Rd, Addison, TX 75001 Phone: 972-851-1022
Hannah Lise Leflore, CF-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15305 Dallas Pkwy Ste 1200, Addison, TX 75001 Phone: 972-851-1022
Miss Lauren Kaitlynn Pybus, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 15820 Addison Rd, Addison, TX 75001 Phone: 866-919-3240

Kailine Hynes, MA, SLP-CCC - Speech-Language Pathologist in Addison, TX